Citadel Advisors’s Ensysce Biosciences ENSC Stock Holding History

Citadel Advisors’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.9K	Buy	+57,363	New	+$36.4K	﹤0.01%	12563
2025 Q4	–	Sell	-14,518	Closed	-$34.4K	–	12983
2025 Q3	$34.4K	Buy	+14,518	New	+$31.2K	﹤0.01%	12354
2024 Q4	–	Sell	-1,574	Closed	-$5.67K	–	14716
2024 Q3	$5.67K	Sell	1,574 -4,182	-73%	-$25.4K	﹤0.01%	13469
2024 Q2	$43.7K	Buy	+5,756	New	+$52.5K	﹤0.01%	11913
2023 Q4	–	Sell	-1,274	Closed	-$26.2K	–	14502
2023 Q3	$26.2K	Buy	+1,274	New	+$36.2K	﹤0.01%	12394
2023 Q1	–	Sell	-235	Closed	-$31.7K	–	14892
2022 Q4	$31.7K	Buy	+235	New	+$112K	﹤0.01%	12670

Other funds holding ENSC

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TIAM2

Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's ENSC Position: Q1 2026 in Review

Citadel Advisors opened a new position in Ensysce Biosciences (ENSC) in Q1 2026: 57,363 shares worth $30.9K. The stake represents ﹤0.01% of the portfolio and ranks #12563 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ENSC as recently as Q3 2025.

Citadel Advisors first reported a position in ENSC in Q4 2022 and has held it in 6 quarters since. The position peaked at $43.7K in Q2 2024. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2026.

Citadel Advisors held 57,363 shares of Ensysce Biosciences worth $30.9K as of Q1 2026.
Ensysce Biosciences was a new Citadel Advisors position in Q1 2026.
Ensysce Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12563 holding.
Citadel Advisors first reported a position in Ensysce Biosciences in Q4 2022 and has held it in 6 quarters since.
Citadel Advisors's Ensysce Biosciences position peaked at $43.7K in Q2 2024.
15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.